NCT02959073

Brief Summary

In the last decades the prevalence of allergies has reached epidemic proportions. 10 to 15% of the population suffers from cat allergy. Investigators perform this study in order to further investigate symptom records and their evaluation in cat allergic patients. Investigators primarily aim to better standardize the symptom recording of cat allergic persons under real-life conditions and to evaluate the effect of hypoallergenic cats on symptom strength.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2016

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 3, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 8, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
Last Updated

May 3, 2017

Status Verified

May 1, 2017

Enrollment Period

5 months

First QC Date

November 3, 2016

Last Update Submit

May 2, 2017

Conditions

Keywords

Symptom recording

Outcome Measures

Primary Outcomes (4)

  • Duration of provocation test under 2 different conditions

    up to 9 weeks

  • Number of score Points resulting from symptom record

    up to 9 weeks

  • fel d 1 concentration in cat dander

    by collecting cat's fur

    up to 9 weeks

  • fel d 1 concentration in the air

    by means of electrostatic dust collectors papers

    up to 9 weeks

Interventions

Subjects muss record their allergic symptoms after contact with their cats

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Healthy male or female participants with age between 18 and 65 years who suffer from confirmed cat allergy. The participants have to own a cat in the house/flat where they live.

You may qualify if:

  • Participant understands the nature, meaning and scope of the study.
  • Signed Informed Consent after being informed.
  • Male and Female patients 18 years to 65 years of age.
  • Positive screening prick test (mean wheal diameter equal or greater 3 mm) when tested with already standardized cat allergen extract.
  • Positive screening prick test (wheal diameter equal or greater 3mm) to Histamine dihydrochloride 10 mg/ml.
  • Positive Scratch Test when tested with cat dander sample of participant's cat.
  • Baseline symptoms with a severity of "1" in at least 2 different symptoms.
  • Owner of a cat that lives in the same household.
  • Cat will not have been washed in the 4 weeks before starting the test phase.

You may not qualify if:

  • Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Positive skin reaction in the prick test to negative control
  • History of anaphylactic reaction to pet allergens
  • Severe diseases influencing the results of the present study by discretion of the investigator
  • Immunotherapy with fel d 1 / cat allergen preparation during the past two years
  • Skin lesions and excessive hair-growth in the skin test areas
  • Treatment with prohibited concomitant medications according to section 8.3 with the exception of medications with local effects which will not influence the results of the skin tests and the results of the other tests (testing period).
  • The patient should not suffer from other respiratory allergies during this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ottawa Allergy Research Corporation (OARC)

Ottawa, Ontario, K1G 6C6, Canada

Location

Study Officials

  • Gabriela Senti Senti, Prof. Dr.

    Hypo Pet AG, c/o University of Zurich

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 3, 2016

First Posted

November 8, 2016

Study Start

September 1, 2016

Primary Completion

February 1, 2017

Study Completion

February 1, 2017

Last Updated

May 3, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share

Locations